These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 15934164

  • 1. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T.
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract] [Full Text] [Related]

  • 2. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P, Scattoni V.
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract] [Full Text] [Related]

  • 3. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.
    Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu K, Naito S, Japan Clinical Oncology Group.
    Jpn J Clin Oncol; 2005 Jan; 35(1):34-6. PubMed ID: 15681602
    [Abstract] [Full Text] [Related]

  • 4. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Urologiia; 2001 Jan; (6):20-1. PubMed ID: 11785074
    [No Abstract] [Full Text] [Related]

  • 5. [Endocrine therapy for prostate cancer in the future].
    Usami M.
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [Abstract] [Full Text] [Related]

  • 6. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G.
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract] [Full Text] [Related]

  • 7. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K, Tomita Y.
    Scand J Urol Nephrol; 2007 Mar; 41(6):558-60. PubMed ID: 17853028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N, Hasegawa Y.
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [Abstract] [Full Text] [Related]

  • 11. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G, Longo F.
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract] [Full Text] [Related]

  • 12. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M, Lacombe L, Fradet Y.
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [Abstract] [Full Text] [Related]

  • 13. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K.
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Rogers C.
    J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
    [No Abstract] [Full Text] [Related]

  • 17. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R, Wieland WF, Bach T, Rössler W, Blana A.
    Dtsch Med Wochenschr; 2007 Jan 26; 132(4):161-6. PubMed ID: 17230333
    [No Abstract] [Full Text] [Related]

  • 18. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA, Strup SE, Gomella LG.
    Tech Urol; 2000 Sep 26; 6(3):221-2. PubMed ID: 10963494
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H, Chodak GW, Hirao Y.
    Gan To Kagaku Ryoho; 2005 Oct 26; 32(10):1507-20. PubMed ID: 16227758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.